BioLife Q2 rev $28.5M (+21% YoY); GAAP net $45.1M incl $42.4M tax benefit; Repligen deal pending Q4

BIOLIFE SOLUTIONS INC

Total revenue $28.5M, up 21% YoY from $23.4M; GAAP gross margin 64%.
GAAP net income $45.1M includes $42.4M non-cash tax benefit from valuation allowance release; adjusted net income $4.2M.
Adjusted EBITDA $7.4M (26% of revenue) vs $5.6M (24%) in Q2 2025.
On July 21, 2026, BioLife agreed to be acquired by Repligen for ~$1.5B enterprise value; expected close Q4 2026.
Biopreservation media used in ~250 ongoing commercial CGT clinical trials (>70% market share); embedded in 18 approved therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.